Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 3/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 0.97 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | RAB9A | P51151 | 2/20 | 0.94 |
| ▸ | NPC1 | O15118 | 1/20 | 0.94 |
| ▸ | POLB | P06746 | 1/20 | 0.94 |
| ▸ | INSR | P06213 | 9/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25298 | 1.00 | APP (1.00) | APPSNCABCHETNFNOD1 | |
| SCHEMBL1577265 | 0.99 | APP (1.00) | APPSNCABCHETNFNOD1 | |
| Bromide SCHEMBL144934 | 0.97 | APP (0.97) | APPSNCABCHETNFNOD1 | |
| SCHEMBL8988031 | 0.89 | APP (0.81) | APPSNCABCHETNFNOD1 | |
| Hydrochloric Acid SCHEMBL39418 | 0.89 | APP (0.80) | APPSNCABCHETNFNOD1 | |
| SCHEMBL19305182 | 0.87 | APP (0.79) | APPSNCABCHETNFNOD1 | |
| Benzoic Acid SCHEMBL21436259 | 0.87 | APP (0.77) | APPSNCABCHETNFNOD1 | |
| Hydrochloric Acid SCHEMBL39277 | 0.85 | SNCA (0.74) | APPSNCABCHETNFNOD1 | |
| SCHEMBL19305181 | 0.83 | SNCA (0.73) | APPSNCABCHETNFNOD1 | |
| SCHEMBL21068083 | 0.83 | APP (0.72) | APPSNCABCHETNFNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4427033-B1 | METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2026-05-20 | — | — | EP | claimed |
| US-20260118346-A1 | METHODS AND RELATED ASPECTS FOR DETERMINING COGNITIVE STATUS ASSOCIATED WITH PARKINSON'S DISEASE | UNIV JOHNS HOPKINS (US) | 2026-04-30 | — | — | US | claimed |
| US-12540949-B2 | Detection of misfolded alpha synuclein protein | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-03 | — | — | US | claimed |
| US-20260029413-A1 | Discriminating Parkinson's Disease from Multiple System Atrophy Using Alpha- Synuclein PMCA | UNIV TEXAS (US) | 2026-01-29 | — | — | US | claimed |
| US-12535488-B2 | Screening method for client protein-protecting protein, and physiologically active protein-stabilizing protein and pharmaceutical composition comprising said protein | THE UNIVERSITY OF TOKYO (JP) | 2026-01-27 | — | — | US | claimed |
| US-20250389732-A1 | Discriminating Parkinson's Disease from Multiple System Atrophy Using Alpha-Synuclein PMCA | AMPRION INC (US) | 2025-12-25 | — | — | US | claimed |
| US-12494072-B2 | Maturity classification of stained reticulocytes using optical microscopy | Siemens Healthineers Ag (DE) | 2025-12-09 | — | — | US | claimed |
| US-20250367264-A1 | GLP-1 ANALOGUE COMPOSITIONS AND PREPARATION METHOD | GALENICUM HEALTH S L U (ES) | 2025-12-04 | — | — | US | claimed |
| EP-4656182-A1 | GLP-1 ANALOGUE COMPOSITIONS AND PREPARATION METHOD | Galenicum Health S.L.U. (ES) | 2025-12-03 | — | — | EP | claimed |
| EP-4656181-A1 | GLP-1 COMPOSITIONS AND PREPARATION METHOD | Galenicum Health S.L.U. (ES) | 2025-12-03 | — | — | EP | claimed |
| US-11313867-B2 | Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-04-26 | — | — | US | claimed |
| WO-2022079297-A1 | ANTIBODIES BINDING TO ALPHA-SYNUCLEIN FOR THERAPY AND DIAGNOSIS | AC IMMUNE SA (CH) | 2022-04-21 | — | — | WO | claimed |
| US-20220108099-A1 | MATURITY CLASSIFICATION OF STAINED RETICULOCYTES USING OPTICAL MICROSCOPY | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2022-04-07 | — | — | US | claimed |
| EP-3978902-A1 | MATURITY CLASSIFICATION OF STAINED RETICULOCYTES USING OPTICAL MICROSCOPY | Siemens Healthcare GmbH (DE) | 2022-04-06 | — | — | EP | claimed |
| EP-3978901-A1 | MATURITY CLASSIFICATION OF STAINED RETICULOCYTES USING OPTICAL MICROSCOPY | Siemens Healthcare GmbH (DE) | 2022-04-06 | — | — | EP | claimed |
| CN-114206444-A | Novel molecules for therapy and diagnosis | AC免疫有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-114181998-A | Simple and sensitive exosome detection method for steric hindrance control signal amplification | 南京大学 | 2022-03-15 | — | — | CN | claimed |
| EP-3956027-A1 | NOVEL MOLECULES FOR THERAPY AND DIAGNOSIS | AC Immune SA (CH) | 2022-02-23 | — | — | EP | claimed |
| US-11249092-B2 | Detection of misfolded tau protein | AMPRION, INC. (US) | 2022-02-15 | — | — | US | claimed |
| US-20220026446-A1 | METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES | AMYLOIDIA SWEDEN AB (SE) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260118346-A1 | METHODS AND RELATED ASPECTS FOR DETERMINING COGNITIVE STATUS ASSOCIATED WITH PARKINSON'S DISEASE | SNCA, PARK7, MAPT | APP 131/4885SNCA 1/4885BCHE 287/4885 |
| US-12535488-B2 | Screening method for client protein-protecting protein, and physiologically active protein-stabilizing protein and pharmaceutical composition comprising said protein | ERP29, SERPINA6, SHBG | APP 735/4885SNCA 1837/4885BCHE 1526/4885 |
| US-12540949-B2 | Detection of misfolded alpha synuclein protein | SNCA, PARK7, NEFM | APP 7/4885SNCA 1/4885BCHE 3110/4885 |
| US-20260029413-A1 | Discriminating Parkinson's Disease from Multiple System Atrophy Using Alpha- Synuclein PMCA | SNCA, PARK7, NEFM | APP 94/4885SNCA 1/4885BCHE 3349/4885 |
| US-20250389732-A1 | Discriminating Parkinson's Disease from Multiple System Atrophy Using Alpha-Synuclein PMCA | SNCA, NEFM, PARK7 | APP 491/4885SNCA 1/4885BCHE 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.